U.S. FDA Decides Against Further Action on Whoop’s Blood Pressure Feature

The U.S. Food and Drug Administration (FDA) has decided not to pursue further enforcement action against wearable company Whoop over its Blood Pressure Insights feature, according to a recent update. The agency initially raised concerns in 2023, but its latest stance reflects a shift in regulatory approach to health technology, according to officials and industry analysts.

What Was the FDA’s Initial Concern?

In October 2023, the FDA sent a warning letter to Whoop, citing that its Blood Pressure Insights feature functioned as a medical device requiring premarket review. The agency stated the tool “intended to provide a measurement or estimation of a user’s blood pressure,” which could be used for diagnosing hypertension or hypotension. “This is a regulated medical device,” an FDA spokesperson said at the time, per a FDA press release.

Whoop argued the feature was designed for general wellness, not clinical diagnosis. CEO Will Ahmed stated, “We won’t let regulatory overreach dictate how people access their own health data,” in a statement published in STAT in November 2023.

Why Did the FDA Change Its Position?

The FDA’s decision to halt enforcement follows ongoing discussions with Whoop about the feature’s intended use. A spokesperson for the agency said, “We continue to evaluate the evolving landscape of digital health tools and their potential impact on public health.” The agency emphasized that its focus remains on ensuring safety but acknowledged the need for flexibility in rapidly advancing technologies.

Industry observers note the move aligns with broader regulatory trends. The FDA has recently issued guidance encouraging innovation in health tech while maintaining safeguards. “This reflects a balance between oversight and fostering technological progress,” said Dr. Sarah Lin, a medical policy analyst at the Pew Charitable Trusts.

What Are the Implications for Health Tech Companies?

The case highlights the challenges of navigating FDA regulations for consumer health devices. Companies like Whoop, Fitbit, and Apple face similar scrutiny as wearables increasingly offer biomedical insights. In 2022, the FDA cleared Apple Watch’s ECG feature after extensive review, illustrating the variability in regulatory outcomes.

Whoop’s Blood Pressure Insights, while not cleared, remains available to users. The company states it “continues to work with regulators to ensure transparency and safety.” However, the lack of formal approval means users should consult healthcare providers for medical decisions, as per the FDA’s standard warnings.

How Does This Fit Into Broader Health Tech Trends?

The dispute underscores tensions between innovation and regulation in digital health. As wearables integrate more advanced diagnostics—such as glucose monitoring and mental health tracking—the line between wellness tools and medical devices grows blurrier. A 2023 report by the National Academy of Medicine warned that “current frameworks may lag behind the pace of technological advancement,” urging updated guidelines.

For now, the FDA’s decision offers a temporary reprieve for Whoop but leaves questions about how similar technologies will be evaluated. “This is a case study in how regulators adapt to new tools,” said Dr. Michael Torres, a health economist at the University of California, San Francisco. “It’s a win for companies pushing boundaries, but patients need clarity on what these tools can and cannot do.”

The situation remains under review, with the FDA expected to issue further guidance later this year. For now, users of Whoop’s feature are advised to treat it as a general health metric rather than a diagnostic tool.